Goldman Sachs
PACB icon

Goldman Sachs’s Pacific Biosciences PACB Stock Holding History

Goldman Sachs’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-75,000
Closed -$985K – 7251
2015
Q4 		$985K Buy
+75,000
New +$673K ﹤0.01% 4312

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's PACB Position: Q2 2026 in Review

Goldman Sachs increased its Pacific Biosciences (PACB) stake by 227% in Q2 2026, buying an estimated $3.26M and bringing the position to 3,229,887 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3814.

Goldman Sachs first reported a position in PACB in Q3 2013 and has held it in 52 quarters since. The position peaked at $91.9M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Goldman Sachs held 3,229,887 shares of Pacific Biosciences worth $5.43M as of Q2 2026.
  • Goldman Sachs bought 2,241,420 Pacific Biosciences shares in Q2 2026, an estimated $3.26M.
  • Pacific Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3814 holding.
  • Goldman Sachs first reported a position in Pacific Biosciences in Q3 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Pacific Biosciences position peaked at $91.9M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.